Moderna says its combination Covid and flu vaccine works well in late-stage trial

Moderna said on Monday its combination vaccine to protect against both Covid and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial.

In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna’s Spikevax mRNA Covid shot, the company said.

The vaccine, called mRNA-1083, elicited a higher immune response against two A strains and one B strain of the flu in older adults when compared with widely used flu shots from GlaxoSmithKline and Sanofi, according to the company.